Generate Biomedicines (NASDAQ:GENB) Reaches New 1-Year High – Here’s Why

Generate Biomedicines Inc (NASDAQ:GENB) shares reached a new 52-week high on Wednesday . The company traded as high as $15.98 and last traded at $15.5890, with a volume of 18490 shares changing hands. The stock had previously closed at $15.49.

Wall Street Analysts Forecast Growth

GENB has been the subject of a number of recent analyst reports. Piper Sandler started coverage on shares of Generate Biomedicines in a report on Tuesday, March 24th. They issued an “overweight” rating and a $24.00 price objective for the company. Zacks Research upgraded Generate Biomedicines to a “hold” rating in a research report on Wednesday, March 25th. Morgan Stanley upped their price target on Generate Biomedicines from $20.00 to $22.00 and gave the stock an “overweight” rating in a report on Thursday. Wall Street Zen downgraded Generate Biomedicines from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, Cantor Fitzgerald initiated coverage on Generate Biomedicines in a report on Tuesday, March 24th. They issued an “overweight” rating on the stock. Six analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $25.40.

Generate Biomedicines Price Performance

The business’s 50 day simple moving average is $12.88.

Generate Biomedicines (NASDAQ:GENB) last announced its earnings results on Thursday, May 7th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.59).

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.